Gianni Virgili: Influence Statistics

Gianni Virgili

Gianni Virgili

Centre for Public Health, Queen’s University of Belfast, Belfast, UK | Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom; Department NEUROFARBA, ...

Gianni Virgili: Expert Impact

Concepts for which Gianni Virgili has direct influence: Visual acuity , Low vision , Laser photocoagulation , Vision impairment , Choroidal neovascularization , Diabetic retinopathy , Optical coherence .

Gianni Virgili: KOL impact

Concepts related to the work of other authors for which for which Gianni Virgili has influence: Diabetic retinopathy , Visual acuity , Uveal melanoma , Choroidal neovascularization , Cataract surgery , Photodynamic therapy , Hip fracture .

KOL Resume for Gianni Virgili

Year
2022

Centre for Public Health, Queen’s University of Belfast, Belfast, UK

Eye Clinic, Department NERUOFARBA, University of Florence, Florence, Italy

Dipartimento di Neuroscienze, Area del Farmaco e Salute del Bambino, Università di Firenze.

2021

Department of Surgery and Translational Medicine, University of Florence, Firenze, Toscana, Italy

Centre for Public Health, Queen’s University of Belfast, Belfast, Northern Ireland, UK

2020

Department of Neurosciences, Psychology, Drug Research and Child Health Eye Clinic, University of Florence, AOU Careggi, 50139 Florence, Italy;, (F.D.);, (L.F.);, (C.L.);, (A.B.);, (R.T.);, (F.G.);, (F.B.);, (A.S.);, (T.C.);, (L.V.);, (A.S.);

Dipartimento organo-muscolo-scheletrico e organi di sensi, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

2019

Department of Translational Surgery and Medicine, Eye Clinic, University of Florence, Florence, Italy

The Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.

2018

Department of Translational Surgery and Medicine, Ophthalmology, University of Florence, Careggi, Florence, Italy.

Careggi Hospital, University of Florence

Prominent publications by Gianni Virgili

KOL-Index: 25226 . BACKGROUND: Diabetic macular oedema (DMO) is a thickening of the central retina, or the macula, and is associated with long-term visual loss in people with diabetic retinopathy (DR). Clinically significant macular oedema (CSMO) is the most severe form of DMO. Almost 30 years ago, the Early Treatment Diabetic Retinopathy Study (ETDRS) found that CSMO, diagnosed by means of stereoscopic ...
Known for Macular Oedema | Optical Coherence | Diabetic Retinopathy | Csmo Patients
KOL-Index: 23405 . BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities can reduce oedema and thereby improve vision and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO. OBJECTIVES: The 2014 update of this ...
Known for Vascular Endothelial | Bevacizumab Ranibizumab | Diabetic Macular Oedema | Growth Factor
KOL-Index: 22612 . BACKGROUND: Corneal endothelial transplantation has become the gold standard for the treatment of corneal endothelial dysfunctions, replacing full thickness transplantation, known as penetrating keratoplasty. Corneal endothelial transplantation has been described using two different techniques: Descemet's membrane endothelial keratoplasty (DMEK) and Descemet's stripping automated ...
Known for Corneal Endothelial | Dmek Dsaek | Stripping Automated | Graft Rejection
KOL-Index: 22071 . BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO, or clinically significant macular oedema (CSMO), vision is rarely improved. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities is used to try to improve ...
Known for Diabetic Macular Oedema | Growth Factor | Vascular Endothelial | Antiangiogenic Therapy
KOL-Index: 21822 . BACKGROUND: Glaucoma is a leading cause of irreversible blindness. A number of minimally-invasive surgical techniques have been introduced as a treatment to prevent glaucoma from progressing; ab interno trabecular bypass surgery with the Schlemm's canal Hydrus microstent is one of them. OBJECTIVES: To evaluate the efficacy and safety of ab interno trabecular bypass surgery with the Hydrus ...
Known for Angle Glaucoma | Cataract Surgery | Proportion Participants | Iop Oag
KOL-Index: 21644 . PURPOSE: To determine whether differences in baseline lesion size and visual acuity might explain differing results found in three different lesion compositions (predominantly classic, minimally classic, and occult with no classic) among three placebo-controlled, randomized clinical trials evaluating photodynamic therapy with verteporfin (Visudyne, Novartis AG), also termed verteporfin ...
Known for Visual Acuity | Lesion Composition | Verteporfin Therapy | Choroidal Neovascularization
KOL-Index: 21170 . BACKGROUND: Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby ...
Known for Bevacizumab Ranibizumab | Systemic Safety | Neovascular Amd | Macular Degeneration
KOL-Index: 20903 . BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO or clinically significant macular oedema (CSMO), vision is rarely improved. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities has recently been proposed for ...
Known for Antiangiogenic Therapy | Diabetic Macular Oedema | Growth Factor | Dmo Laser Photocoagulation
KOL-Index: 19828 . BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) can reduce oedema, improve vision and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO. OBJECTIVES: The 2014 update of this review found ...
Known for Bevacizumab Ranibizumab | Growth Factor | Diabetic Macular Oedema | Vascular Endothelial
KOL-Index: 19587 . BACKGROUND: Diabetic retinopathy is a complication of diabetes in which high blood sugar levels damage the blood vessels in the retina. Sometimes new blood vessels grow in the retina, and these can have harmful effects; this is known as proliferative diabetic retinopathy. Laser photocoagulation is an intervention that is commonly used to treat diabetic retinopathy, in which light energy is ...
Known for Laser Photocoagulation | Diabetic Retinopathy | Visual Acuity | 12 Months
KOL-Index: 19465 . BACKGROUND: Age-related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents: aflibercept, ranibizumab, and off-label bevacizumab. Injections can be given monthly, every two or three months ...
Known for Vascular Endothelial | Macular Degeneration | Monthly Injections | Lowcertainty Evidence
KOL-Index: 17707 . BACKGROUND: Contemporary data for causes of vision impairment and blindness form an important basis of recommendations in public health policies. Refreshment of the Global Vision Database with recently published data sources permitted modelling of cause of vision loss data from 1990 to 2015, further disaggregation by cause, and forecasts to 2020. METHODS: In this systematic review and ...
Known for Vision Impairment | Global Population | Cataract Glaucoma | Agerelated Macular Degeneration
KOL-Index: 17240 . PURPOSE: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin in patients with subfoveal choroidal neovascularization (CNV) caused by pathologic myopia. DESIGN AND SETTING: Multicenter, double-masked, placebo-controlled, randomized clinical trial at 28 ophthalmology practices in Europe and North America. PARTICIPANTS: ...
Known for Verteporfin Therapy | Subfoveal Choroidal | 1 Year | Clinical Trial
KOL-Index: 16917 . BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. The retina at the macula thickens and this can cause gradual loss of central vision. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO or clinically significant macular oedema (CSMO), vision is rarely improved. Antiangiogenic therapy with ...
Known for Antiangiogenic Therapy | Diabetic Macular Oedema | Growth Factor | Monoclonal Antibodies
KOL-Index: 16697 . BACKGROUND: Diabetic macular oedema (DMO) is a thickening of the central retina, or the macula, and is associated with long-term visual loss in people with diabetic retinopathy (DR). Clinically significant macular oedema (CSMO) is the most severe form of DMO. Almost 30 years ago, the Early Treatment Diabetic Retinopathy Study (ETDRS) found that CSMO, diagnosed by means of stereoscopic ...
Known for Macular Oedema | Optical Coherence | Diabetic Retinopathy | Retinal Thickness

Key People For Visual Acuity

Top KOLs in the world
#1
Paul A Mitchell
visual impairment diabetic retinopathy cataract surgery
#2
Ronald E Klein
diabetic retinopathy beaver dam atherosclerosis risk
#3
Frederick L III Ferris
diabetic retinopathy visual acuity macular edema
#4
Neil M Bressler
visual acuity diabetic macular edema choroidal neovascularization
#5
Barbara E K Klein
diabetic retinopathy beaver dam blood pressure
#6
Wong Tien Yin Wong
diabetic retinopathy blood pressure retinal vascular caliber

Centre for Public Health, Queen’s University of Belfast, Belfast, UK | Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom; Department NEUROFARBA, University of Florence, Florence, Italy. | Centre for Public Health, Queen's